Doxazosin labels and packages: Difference between revisions
Created page with "__NOTOC__ {{Doxazosin}} {{CMG}}; {{AE}} {{AK}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = DOXAZOSIN TABLET [APOTEX CORP.] | url = http:/..." |
No edit summary |
||
Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AK}} | {{CMG}}; {{AE}} {{AK}} | ||
PRINCIPAL DISPLAY PANEL FOR 1 MG 100s | |||
Representative sample of labeling (see [[Doxazosin how supplied storage and handling|HOW SUPPLIED]]] section of complete listing): | |||
APOTEX CORP. | |||
NDC 60505-0093-0 Doxazosin Tablets, USP1mgRx100 count | |||
{| | |||
| [[image:doxa8.jpg|400px|thumb]] | |||
|} | |||
PRINCIPAL DISPLAY PANEL FOR 2 MG 100s | |||
Representative sample of labeling (see [[Doxazosin how supplied storage and handling|HOW SUPPLIED]] section of complete listing): | |||
APOTEX CORP. | |||
NDC 60505-0094-0 Doxazosin Tablets, USP2mgRx100 count | |||
{| | |||
| [[image:doxa9.jpg|400px|thumb]] | |||
|} | |||
PRINCIPAL DISPLAY PANEL FOR 4 MG 100s | |||
Representative sample of labeling (see [[Doxazosin how supplied storage and handling|HOW SUPPLIED]] section of complete listing): | |||
APOTEX CORP. | |||
NDC 60505-0095-0 Doxazosin Tablets, USP4mgRx100 count | |||
{| | |||
| [[image:doxa10.jpg|400px|thumb]] | |||
|} | |||
PRINCIPAL DISPLAY PANEL FOR 8 MG 100s | |||
Representative sample of labeling (see [[Doxazosin how supplied storage and handling|HOW SUPPLIED]] section of complete listing): | |||
APOTEX CORP. | |||
NDC 60505-0096-0 Doxazosin Tablets, USP8mgRx100 count | |||
{| | |||
| [[image:doxa11.jpg|400px|thumb]] | |||
|} | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = DOXAZOSIN TABLET [APOTEX CORP.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4fa5c2f7-cda9-56cd-622f-b3d05dc7c94b | publisher = | date = | accessdate = 7 March 2014 }}</ref> | <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = DOXAZOSIN TABLET [APOTEX CORP.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4fa5c2f7-cda9-56cd-622f-b3d05dc7c94b | publisher = | date = | accessdate = 7 March 2014 }}</ref> | ||
Revision as of 05:39, 7 March 2014
Doxazosin |
---|
Doxazosin®, Cardura® FDA Package Insert |
Indications and Usage |
Dosage and Administration |
Contraindications |
Warnings |
Precautions |
Adverse Reactions |
Drug Interactions |
Use in Specific Populations |
Overdosage |
Description |
Clinical Pharmacology |
Nonclinical Toxicology |
How Supplied/Storage and Handling |
Patient Counseling Information |
Labels and Packages |
Clinical Trials on Doxazosin |
ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
PRINCIPAL DISPLAY PANEL FOR 1 MG 100s
Representative sample of labeling (see HOW SUPPLIED] section of complete listing): APOTEX CORP.
NDC 60505-0093-0 Doxazosin Tablets, USP1mgRx100 count
PRINCIPAL DISPLAY PANEL FOR 2 MG 100s
Representative sample of labeling (see HOW SUPPLIED section of complete listing): APOTEX CORP.
NDC 60505-0094-0 Doxazosin Tablets, USP2mgRx100 count
PRINCIPAL DISPLAY PANEL FOR 4 MG 100s
Representative sample of labeling (see HOW SUPPLIED section of complete listing): APOTEX CORP.
NDC 60505-0095-0 Doxazosin Tablets, USP4mgRx100 count
PRINCIPAL DISPLAY PANEL FOR 8 MG 100s
Representative sample of labeling (see HOW SUPPLIED section of complete listing): APOTEX CORP.
NDC 60505-0096-0 Doxazosin Tablets, USP8mgRx100 count
References
- ↑ "DOXAZOSIN TABLET [APOTEX CORP.]". Retrieved 7 March 2014.